Stereotaxis (NYSE:STXS) today announced the first treated patients in the U.S. as part of its surgical robotics collaboration with Abbott
(NYSE: ABT)
.
In May, the two companies entered a deal aimed at taking robotic electrophysiology to the next level. It sought to integrate the Abbott EnSite X EP 3D heart mapping system — with Stereotaxis’ robotic magnetic navigation systems. The collaboration combines real-time diagnostic information with the precision and stability of surgical robotics.
Physicians across four U.S. medical centers completed the first integrated procedures in the U.S. They took place at Weill Cornell Medical Center, Mount Sinai Morningside, Banner University Medical Center Phoenix, and Overland Park Regional Medical Center.
Dr. Dhanunjaya Lakkireddy of Overland took part in the initial cases. Lakkireddy said in a news release that the combination of technologies enhanced precision and streamlined procedure workflow. Dr. Jim Cheung of Weill added that the doctors leveraged “the combined benefits in diagnosis and therapy for our patients.”
Mount Sinai’s Dr. Ranjit Suri noted that the “increased physician choice and technology interoperability” benefits everyone involved.
Dr. J. Peter Weiss of Banner said the successful procedures demonstrate the collaboration’s “unmatched potential.” He also cited the importance of increased collaboration in the field of electrophysiology.
“The combined benefits of advanced mapping and robotic technologies allows us to envision a new era of cardiac care where personalized therapy is designed and delivered to each individual patient. It’s a game-changer for the field,” Weiss said.
